Who
Stephen A. Sherwin
Director
Company insider
Files Form 4 as: Director, Neurocrine Biosciences; Director, Biogen; Director, Neon Therapeutics; Director, Aduro Biotech; Director, Rigel Pharmaceuticals; Director, Verastem; Director, Vical; Director, ANI Pharmaceuticals.
In numbers
- Trades disclosed
- 217
- Buys
- 2
- Sells
- 16
- Bought
- $21K
- Sold
- $32.8M
- Companies
- 9
- Companies where not an officer
- 8
- First trade
- 7 Feb 2006
- Last trade
- 2 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 3 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code G | —1,000 at $0.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code G | —1,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —1,505 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —1,505 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $805K15,000 at $53.64 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $798K10,000 at $79.79 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.3M7,883 at $163.81 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $419K2,549 at $164.44 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.1M6,896 at $165.79 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $971K5,829 at $166.56 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $308K1,843 at $167.31 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $805K15,000 at $53.64 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $798K10,000 at $79.79 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.3M7,883 at $163.81 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $419K2,549 at $164.44 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.1M6,896 at $165.79 | filing |
News
Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)NBIX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Stephen A. Sherwin; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.